The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...

Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...

For investors in Novo Nordisk (NYSE: NVO), 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting competitive ...

Novo Nordisk NOVO B announced plans on Oct. 9 to acquire Akero Therapeutics and its phase 3 FGF21 analog efruxifermin for USD 4.7 billion upfront and a potential additional USD 500 million contingent ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

Former Novo Nordisk CSO Marcus Schindler on R&D leadership, pharma innovation, scientific discovery, AI, global talent, DEI, biotech, drug development strategy.

Going "beyond the pill" doesn't just mean devising new digital technologies to market a drug or promote medication adherence with software tools. Sometimes it means engaging patients in their patient ...

Novo Nordisk is set to lay off roughly 9,000 employees across its global workforce of 78,400 as part of a newly launched restructuring initiative. In a Sept. 10 press release, the Danish ...

Novo Nordisk said it would replace its chairman and other board members after the Danish pharma giant's controlling shareholder pushed for more changes to revive the company's success in the ...

One day after announcing plans to cut 9,000 jobs in a major restructuring, Novo Nordisk has told its employees that office work will be mandatory at the start of next year. There is some flexibility ...